MINI FUTURE SHORT - BRISTOL-MYERS SQUIBB | Delayed Deutsche Boerse AG 09:35:25 2024-06-28 EDT | ||
| 2.49 EUR | -1.97% |
|
| Current month | -0.78% | ||
| 1 month | +1.60% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-06-28 | 2.49 | -1.97% |
| 24-06-27 | 2.54 | +3.25% |
| 24-06-26 | 2.46 | -0.40% |
| 24-06-25 | 2.47 | 0.00% |
| 24-06-24 | 2.47 | -1.98% |
Delayed Quote Deutsche Boerse AG
Last update June 28, 2024 at 09:35 am
More quotesStatic data
| Product type | Knock-Out con Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
BNP Paribas
|
| WKN | PN3Z3E |
| ISIN | DE000PN3Z3E9 |
| Date issued | 2023-05-26 |
| Strike | 68.63 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.45 € |
| Emission volume | N/A |
| Settlement | Por diferencias |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.67 € |
|---|---|
| Lowest since issue | 0.33 € |
| Spread | 0.01 € |
| Spread % | 0.39% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.51
USD
Average target price
53.19
USD
Spread / Average Target
+28.15%
- Stock Market
- Certificates
- Certificat
